Title: Breast cancer screening of mutation carriers in the era of COVID‐19 pandemic
Abstract: International Journal of CancerVolume 147, Issue 12 p. 3574-3575 Letter to the Editor Breast cancer screening of mutation carriers in the era of COVID-19 pandemic Angela Toss, Corresponding Author Angela Toss [email protected] orcid.org/0000-0002-1854-6701 Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance, University of Modena and Reggio Emilia, Modena, Italy Correspondence Angela Toss, Department of Oncology and Hematology, University Hospital of Modena, Via del Pozzo 71, Modena 41124, Italy. Email: [email protected]Search for more papers by this authorMatteo Lambertini, Matteo Lambertini orcid.org/0000-0003-1797-5296 Department of Medical Oncology, U.O.C Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, ItalySearch for more papers by this authorKevin Punie, Kevin Punie Department of General Medical Oncology, University Hospitals Leuven, Leuven, BelgiumSearch for more papers by this authorGiovanni Grandi, Giovanni Grandi Department of Obstetrics, Gynecology and Pediatrics, Obstetrics and Gynecology Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, ItalySearch for more papers by this authorLaura Cortesi, Laura Cortesi orcid.org/0000-0001-8950-8561 Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, ItalySearch for more papers by this author Angela Toss, Corresponding Author Angela Toss [email protected] orcid.org/0000-0002-1854-6701 Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance, University of Modena and Reggio Emilia, Modena, Italy Correspondence Angela Toss, Department of Oncology and Hematology, University Hospital of Modena, Via del Pozzo 71, Modena 41124, Italy. Email: [email protected]Search for more papers by this authorMatteo Lambertini, Matteo Lambertini orcid.org/0000-0003-1797-5296 Department of Medical Oncology, U.O.C Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, ItalySearch for more papers by this authorKevin Punie, Kevin Punie Department of General Medical Oncology, University Hospitals Leuven, Leuven, BelgiumSearch for more papers by this authorGiovanni Grandi, Giovanni Grandi Department of Obstetrics, Gynecology and Pediatrics, Obstetrics and Gynecology Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, ItalySearch for more papers by this authorLaura Cortesi, Laura Cortesi orcid.org/0000-0001-8950-8561 Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, ItalySearch for more papers by this author First published: 17 June 2020 https://doi.org/10.1002/ijc.33160Citations: 2Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Tagliamento M, Lambertini M, Genova C, et al. Call for ensuring cancer care continuity during COVID-19 pandemic. ESMO Open. 2020; 5(3):e000783. 10.1136/esmoopen-2020-000783 PubMedWeb of Science®Google Scholar 2Dietz JR, Moran MS, Isakoff SJ, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. The COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020; 181(3): 487-497. 10.1007/s10549-020-05644-z CASPubMedWeb of Science®Google Scholar 3Soran A, Gimbel M, Diego E. Breast cancer diagnosis, treatment and follow-up during COVID-19 pandemic. Eur J Breast Health. 2020; 16(2): 86-88. 10.5152/ejbh.2020.240320 PubMedWeb of Science®Google Scholar 4Curigliano G, Cardoso MJ, Poortmans P, et al. Editorial board of the breast, recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. Breast. 2020; 52: 8-16. https://doi.org/10.1016/j.breast.2020.04.006. 10.1016/j.breast.2020.04.006 PubMedWeb of Science®Google Scholar 5Lambertini M, Toss A, Passaro A, et al. Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective. ESMO Open. 2020; 5(2):e000759. 10.1136/esmoopen-2020-000759 PubMedWeb of Science®Google Scholar 6de Azambuja E, Trapani D, Loibl S, et al. ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer. ESMO Open. 2020; 5:e000793. 10.1136/esmoopen-2020-000793 PubMedWeb of Science®Google Scholar 7Special communication: Gestione delle pazienti con carcinoma mammario durante la pandemia COVID-19. https://www.aiom.it/wp-content/uploads/2020/05/20200425_GestioneBCduranteCOVID-19.pdf. Accessed on 28 May, 2020. Google Scholar 8Pálka I, Kelemen G, Ormándi K, et al. Tumor characteristics in screen-detected and symptomatic breast cancers. Pathol Oncol Res. 2008 Jun; 14(2): 161-167. 10.1007/s12253-008-9010-7 PubMedWeb of Science®Google Scholar 9Kirsh VA, Chiarelli AM, Edwards SA, et al. Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program. J Natl Cancer Inst. 2011; 103(12): 942-950. 10.1093/jnci/djr138 PubMedGoogle Scholar 10Kobayashi N, Hikichi M, Ushimado K, et al. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival. Clin Transl Oncol. 2017; 19(10): 1232-1240. 10.1007/s12094-017-1660-z CASPubMedWeb of Science®Google Scholar 11Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet. 1999; 353(9159): 1119-1126. 10.1016/S0140-6736(99)02143-1 CASPubMedWeb of Science®Google Scholar 12Maringe C, Walters S, Butler J, et al. Stage at diagnosis and ovarian cancer survival: evidence from the international cancer benchmarking partnership. Gynecol Oncol. 2012; 127(1): 75-82. 10.1016/j.ygyno.2012.06.033 PubMedWeb of Science®Google Scholar 13Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in new York City: prospective cohort study. BMJ. 2020; 369:m1966. 10.1136/bmj.m1966 PubMedGoogle Scholar 14Grandi G, Facchinetti F, Bitzer J. The gendered impact of coronavirus disease (COVID-19): do estrogens play a role? Eur J Contracept Reprod Health Care. 2020; 25(3): 233-234. 10.1080/13625187.2020.1766017 PubMedWeb of Science®Google Scholar Citing Literature Volume147, Issue1215 December 2020Pages 3574-3575 This article also appears in:World Cancer Day 2021 ReferencesRelatedInformation